NEW YORK, June 13 (GenomeWeb News) - Advanced Chemistry Development (ACD/Labs) said last week that GlaxoSmithKline will deploy its NMR Prediction and Processing software modules across its worldwide discovery research centers.
Under the agreement, scientists at GSK research centers in Europe and the US will use ACD/Labs NMR Processors for processing and analysis, as well as the ACD/CNMR Predictor for calculating chemical shifts and coupling constants for 13C NMR spectra. ACD/2D NMR Manager will also be installed at various locations to provide specialists with 2D NMR verification capabilities, the company said.
ACD/Combi NMR will also be installed at GSK's Stevenage, UK, and Research Triangle Park, NC, sites.
Financial terms for the licensing agreement were not disclosed.